Pituitary T1 signal intensity at magnetic resonance imaging is reduced in patients with obesity: results from the CHIASM study.
Journal
International journal of obesity (2005)
ISSN: 1476-5497
Titre abrégé: Int J Obes (Lond)
Pays: England
ID NLM: 101256108
Informations de publication
Date de publication:
10 2023
10 2023
Historique:
received:
05
08
2022
accepted:
04
07
2023
revised:
18
06
2023
medline:
22
9
2023
pubmed:
22
7
2023
entrez:
21
7
2023
Statut:
ppublish
Résumé
Despite obesity being well known to be associated with several pituitary hormone imbalances, pituitary appearance in magnetic resonance imaging (MRI) in patients with obesity is understudied. To evaluate the pituitary volume and signal intensity at MRI in patients with obesity. This is a prospective study performed in an endocrine Italian referral center (ClinicalTrial.gov Identifier: NCT03458533). Sixty-nine patients with obesity (BMI > 30 kg/m At baseline, no difference in pituitary volume was observed between the obese and non-obese cohorts. At the 3-year follow-up, pituitary volume was significantly reduced (p = 0.011) only in participants with stable-increased body weight. Furthermore, a significant difference was noted in the mean pituitary intensity of T1-weighted plain and contrast-enhanced sequences between the obese and non-obese cohorts at baseline (p = 0.006; p = 0.002), and a significant decrease in signal intensity was observed in the subgroup of participants who had not lost weight (p = 0.012; p = 0.017). Insulin-like growth factor-1 levels, following correction for BMI, were correlated with pituitary volume (p = 0.001) and intensity (p = 0.049), whereas morning cortisol levels were correlated with pituitary intensity (p = 0.007). The T1-weighted pituitary intensity was negatively correlated with truncal fat (p = 0.006) and fibrinogen (p = 0.018). The CHIASM study describes a quantitative reduction in pituitary intensity in T1-weighted sequences in patients with obesity. These alterations could be explained by changes in the pituitary stromal tissue, correlated with low-grade inflammation.
Sections du résumé
BACKGROUND
Despite obesity being well known to be associated with several pituitary hormone imbalances, pituitary appearance in magnetic resonance imaging (MRI) in patients with obesity is understudied.
OBJECTIVE
To evaluate the pituitary volume and signal intensity at MRI in patients with obesity.
METHODS
This is a prospective study performed in an endocrine Italian referral center (ClinicalTrial.gov Identifier: NCT03458533). Sixty-nine patients with obesity (BMI > 30 kg/m
RESULTS
At baseline, no difference in pituitary volume was observed between the obese and non-obese cohorts. At the 3-year follow-up, pituitary volume was significantly reduced (p = 0.011) only in participants with stable-increased body weight. Furthermore, a significant difference was noted in the mean pituitary intensity of T1-weighted plain and contrast-enhanced sequences between the obese and non-obese cohorts at baseline (p = 0.006; p = 0.002), and a significant decrease in signal intensity was observed in the subgroup of participants who had not lost weight (p = 0.012; p = 0.017). Insulin-like growth factor-1 levels, following correction for BMI, were correlated with pituitary volume (p = 0.001) and intensity (p = 0.049), whereas morning cortisol levels were correlated with pituitary intensity (p = 0.007). The T1-weighted pituitary intensity was negatively correlated with truncal fat (p = 0.006) and fibrinogen (p = 0.018).
CONCLUSIONS
The CHIASM study describes a quantitative reduction in pituitary intensity in T1-weighted sequences in patients with obesity. These alterations could be explained by changes in the pituitary stromal tissue, correlated with low-grade inflammation.
Identifiants
pubmed: 37479795
doi: 10.1038/s41366-023-01338-w
pii: 10.1038/s41366-023-01338-w
pmc: PMC10511316
doi:
Substances chimiques
Fibrinogen
9001-32-5
Banques de données
ClinicalTrials.gov
['NCT03458533']
Types de publication
Journal Article
Review
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
948-955Commentaires et corrections
Type : ErratumIn
Informations de copyright
© 2023. The Author(s).
Références
Int J Obes Suppl. 2019 Apr;9(1):50-64
pubmed: 31391924
Obes Res. 2005 Jul;13(7):1157-66
pubmed: 16076984
PLoS One. 2016 Jan 29;11(1):e0147575
pubmed: 26824435
Endocrine. 2015 Jun;49(2):503-11
pubmed: 25614038
Neuroradiol J. 2020 Oct;33(5):400-409
pubmed: 32666872
N Engl J Med. 1984 Nov 29;311(22):1403-7
pubmed: 6436706
Nat Methods. 2012 Jul;9(7):671-5
pubmed: 22930834
Invest Radiol. 1997 Jun;32(6):320-9
pubmed: 9179706
J Clin Endocrinol Metab. 2001 Aug;86(8):3845-52
pubmed: 11502822
J Clin Invest. 2020 Aug 3;130(8):4094-4103
pubmed: 32315289
Pol Merkur Lekarski. 2021 Jun 16;49(291):187-192
pubmed: 34218236
J Laparoendosc Adv Surg Tech A. 2018 Aug;28(8):919-924
pubmed: 30010474
Epidemiol Rev. 2007;29:1-5
pubmed: 17569676
Eur J Endocrinol. 2016 Oct;175(4):255-63
pubmed: 27418059
Endocrinology. 2014 Aug;155(8):2858-67
pubmed: 24914942
Int J Mol Sci. 2020 Dec 20;21(24):
pubmed: 33419306
Obes Rev. 2002 May;3(2):85-101
pubmed: 12120424
J Clin Invest. 2012 Jan;122(1):153-62
pubmed: 22201683
Int J Endocrinol. 2021 May 29;2021:6663553
pubmed: 34135958
Prog Neuropsychopharmacol Biol Psychiatry. 2011 Jan 15;35(1):177-83
pubmed: 21044655
Eur J Endocrinol. 2020 Jan;182(1):11-21
pubmed: 31652416
Public Health Nutr. 2011 Dec;14(12A):2274-84
pubmed: 22166184
Am J Med Genet A. 2008 Mar 1;146A(5):570-7
pubmed: 17431897
Dis Model Mech. 2017 Jun 1;10(6):679-689
pubmed: 28592656
Endocr Relat Cancer. 2016 Nov;23(11):871-881
pubmed: 27649724
Neuroradiology. 2016 Jan;58(1):51-7
pubmed: 26376802
Cell J. 2019 Jan;20(4):604-607
pubmed: 30124010
Urol Clin North Am. 2016 May;43(2):239-45
pubmed: 27132582
Endocrinol Metab Clin North Am. 2020 Jun;49(2):239-250
pubmed: 32418587
Clin Endocrinol (Oxf). 2008 Oct;69(4):648-52
pubmed: 18346211
J Pediatr Endocrinol Metab. 2016 Oct 1;29(10):1195-1200
pubmed: 27710916
Clin Endocrinol (Oxf). 2014 Sep;81(3):378-86
pubmed: 24237302
J Clin Endocrinol Metab. 1998 Jun;83(6):1853-9
pubmed: 9626108
Obes Facts. 2015;8(6):402-24
pubmed: 26641646
Pituitary. 2021 Oct;24(5):737-745
pubmed: 33973151
J Clin Endocrinol Metab. 1991 Jan;72(1):51-9
pubmed: 1986027
Transl Behav Med. 2016 Sep;6(3):339-46
pubmed: 27528523
Am J Clin Nutr. 1995 Feb;61(2):274-8
pubmed: 7840063
Endocrinol Metab Clin North Am. 2003 Dec;32(4):895-914
pubmed: 14711067
Diabetes Metab. 2015 Jun;41(3):248-51
pubmed: 25541439
Australas Radiol. 2000 Aug;44(3):341-8
pubmed: 10974735
Eur J Endocrinol. 2022 Apr 21;186(6):R79-R92
pubmed: 35333754
World Neurosurg. 2019 Jan;121:e449-e457
pubmed: 30267949
Rev Endocr Metab Disord. 2020 Sep;21(3):315-327
pubmed: 32829455
Eur J Endocrinol. 2017 Dec;177(6):R275-R285
pubmed: 28780516